NRK EKKO med innslag om vår porteføljebedrift Vaccibody.
Our portfolio company Targovax reports encouraging disease-free survival (DFS) data from TG01 trial in resected pancreatic cancer: 16.1 months median DFS with TG01 and gemcitabine combination for all 32 patients in the trial 19.5 months DFS in 2nd cohort who received an optimized dosing regimen 94% of patients had mutant RAS specific adaptive immune activation […]
Our portfolio company Vaccibody has released an update on the clinical trial of their neoantigen cancer vaccine in phase I/II: 10 patients have been enrolled and vaccination has started. Mads Axelsen, MD, Chief Medical Officer in Vaccibody, said in a press release: “We are very pleased with the enrollment in the neoantigen trial and […]
Our portfolio company Targovax has released interim results from the phase I trial of ONCOS-102 in checkpoint inhibitor refractory melanoma. Dr. Magnus Jäderberg, CMO of Targovax, said in a press release from the company: “Given the limited number of patients who have completed the study to date, it is encouraging to already see a complete […]
Our portolio company Vaccibody AS just entered a clinical collaboration with U.S. company Nektar Therapeutics. The aim of the collaboration is to evaluate Vaccibody’s personalized cancer neoantigen vaccine, VB10.NEO, in combination with Nektar’s immune treatment NKTR-214, which is a CD-122-biased agonist. In an interview with Norwegian financial paper “Finansavisen”, President and CSO in Vaccibody, […]
Our portfolio company Photocure ASA has appointed Daniel Schneider as Chief Exceutive Officer and President. Mr Schneider joins Photocure from the position of General Manager for Ablynx N.V. in North America. Mr Schneider will commence the position upon further agreement, expected prior to 1 November 2018. Erik Dahl will continue to serve as the acting […]
Vi har nå kommet til episode 50 i vår podkast RADIUM. Det feires med en live innspilling. Vi skal snakke om et tema som RADFORSK er veldig engasjert i, nemlig kliniske studier. Studiene er helt avgjørende for å utvikle kreftbehandling, og det er enormt viktig at norske kreftpasienter får ta del i dette. I […]
Our portfolio company Nordic Nanovector provided an update on its clinical development programme, including updated guidance on expected milestones for the pivotal PARADIGME trial in early April. At the same time CEO Luigi Costa informed that he would resign from his position. View a webcast of the update Download presentation on the update Press […]
The news got the front page of VG.